Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

112.57 +2.30 (+2.09%)

Streaming Delayed Price Updated: 1:15 PM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Balancing Dividends and Fundamentals: The Case of NYSE:MRK. ↗

January 28, 2025

Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics.

Via Chartmill

Why This Beaten-Down Stock Is a Buy in 2025 and Beyond ↗

January 27, 2025

Via The Motley Fool

FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)

January 27, 2025

From Merck & Co., Inc.

Via Business Wire

These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗

January 25, 2025

Via The Motley Fool

Topics Stocks

Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study ↗

January 24, 2025

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Via Benzinga

NYSE:MRK is probably undervalued for the fundamentals it is displaying. ↗

January 23, 2025

MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals.

Via Chartmill

Price Over Earnings Overview: Merck & Co ↗

January 15, 2025

Via Benzinga

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots ↗

January 24, 2025

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Via Investor's Business Daily

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

January 24, 2025

From Merck & Co., Inc.

Via Business Wire

RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing ↗

January 23, 2025

Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality.

Via Benzinga

Topics Lawsuit

3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗

January 23, 2025

Via The Motley Fool

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗

January 22, 2025

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Via Benzinga

Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines ↗

January 22, 2025

Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine.

Via Investor's Business Daily

Topics Artificial Intelligence

Why Summit Therapeutics Stock Is Jumping Today ↗

January 21, 2025

Via The Motley Fool

Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗

January 21, 2025

Via The Motley Fool

Topics Stocks

Earnings Season Scorecard And Fresh Analyst Reports For Chevron, Merck & Others ↗

January 20, 2025

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, Merck & Co., Inc., and QUALCOMM Incorporated, as well as two micro-cap stocks CSP Inc. and AMCON...

Via Talk Markets

Topics Stocks / Equities

Healthcare And Biotech Stocks Lag The Market Again ↗

January 20, 2025

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Via Talk Markets

Topics Stocks / Equities

AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion ↗

January 18, 2025

Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,...

Via Talk Markets

Topics Artificial Intelligence Stocks / Equities

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4

January 16, 2025

From Merck & Co., Inc.

Via Business Wire

3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever ↗

January 16, 2025

The time to step into quality dividend payers is when the crowd forgets there's never a bad time to own a high-quality stock.

Via The Motley Fool

Topics Stocks

What Lies Ahead In 2025? Slower Growth, More Volatility ↗

January 14, 2025

As we move through 2025, the global economy and financial markets are facing a critical juncture.

Via Talk Markets

Topics Economy Stocks / Equities

Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell? ↗

January 14, 2025

Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.

Via Investor's Business Daily

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

January 08, 2025

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

Via MarketBeat

Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 08, 2025

Via Benzinga

This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

January 08, 2025

Via Benzinga

Merck’s GARDASIL® Receives Expanded Approval for Males in China

January 08, 2025

From Merck & Co., Inc.

Via Business Wire

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗

January 07, 2025

Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments.

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.